MOUNTAIN VIEW, Calif., Oct. 2, 2012 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today preclinical results for CCX872, the Company’s next-generation, orally bioavailable inhibitor of the chemokine receptor known as CCR2. The findings showed that treatment with CCX872 improved multiple parameters of renal function in an in vivo model of diabetic nephropathy. The data were reported in an oral presentation titled, “CCR2 Inhibition Improves Renal Function in Diabetic BTBR ob/ob Mice,” at the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) taking place in Berlin.
